ARTICLE | Emerging Company Profile
Maraganore’s latest RNA company pairs targeting tech with trigger molecules a fraction of the size of Alnylam’s
By Richard Guy, Biopharma Analyst
December 20, 2024 10:03 PM UTC
Launched on Oct. 8 with a $135 million series A round led by Arch, City Therapeutics — John Maraganore’s latest RNA company — is using shorter siRNA sequences to overcome the challenges of targeting tissues other than the liver.
After leading Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) for almost two decades, Maraganore retired at the end of 2021, joining Arch Venture Partners where he’s invested in new RNA companies, either taking an advisory role or board seat. For City Therapeutics Inc., he opted to become executive chair…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654191/city-taking-rnai-beyond-the-liver